Good glycaemic control: An international perspective on bridging the gap between theory and practice in type 2 diabetes

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2651-2661

  Kilpatrick, Eric S ^a,e   Das, A K ^b   Orskov C ^c   Berntorp, K ^d  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c NOVO NORDISK A S   (Denmark)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Global Task Force (GTF) on Glycaemic Control

Author keywords

Glycaemic control; Guidelines; HbA1c; Insulin; Type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LONG ACTING DRUG; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; BEDTIME DOSAGE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETIC NEPHROPATHY; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MEDLINE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; RISK REDUCTION; SELF MONITORING; SOCIOECONOMICS; THEORETICAL STUDY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GUIDELINES AS TOPIC; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PATIENT COMPLIANCE;

EID: 53349141647     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802347209     Document Type: Article

References (75)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7
2. Economist Intelligence Unit. Silent epidemic: an economic study of diabetes in developed and developing countries. London: Economist Intelligence Unit; 2007
3. NICE, National Institute for Clinical Excellence. Guidelines. Diabetic Med 2005;22(Suppl 1):5-6
4. AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
5. Asian-Pacific Type 2 Diabetes Policy Group, editor. Type 2 diabetes practical targets and treatments, 4th ed. Melbourne, Singapore: International Diabetes Institute and In vivo Communications; 2005
6. Anon. International Diabetes Federation global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Med 2006;23:579-93
7. ADA. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30:S4-S41
8. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-53
9. Chuang LM, Tsai ST, Huang BY, et al. The status of diabetes control in Asia - a cross-sectional survey of 24317 patients with diabetes mellitus in 1998. Diabetic Med 2002; 19:978-85
10. Raheja BS, Kapur A, Bhoraskar A, et al. DiabCare Asia - India study: diabetes care in India - current status. J Assoc Physicians India 2001;49:717-22
11. Liebt A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002;110:10-6
12. Charpentier G, Genes N, Vaur L, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003; 29:152-8
13. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002;45:23-28
14. Zwar NA, Hermiz O, Comino EJ, et al. Do multidisciplinary care plans result in better care for patients with type 2 diabetes? Aust Fam Physician 2007;36:85-9
15. Mainous 3rd AG, Diaz VA, Saxena S, et al. Diabetes management in the USA and England: comparative analysis of national surveys. J R Soc Med 2006;99:463-9
16. Ko SH, Song KH, Kim SR, et al. Long-term effects of a structured intensive diabetes education programme (SIDEP) in patients with Type 2 diabetes mellitus - a 4-year follow-up study. Diabetic Med 2007;24:55-62
17. Stratton IM, Adler Al, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J (Clinical Research edition) 2000;321:405-12
18. Schiel R, Muller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). Exp Clin Endocrinol Diabetes 1999;107:506-11
19. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39:1540-5
20. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
21. Rhee SY, Kim YS, Oh S, et al. Diabcare Asia 2001 - Korea country report on outcome data and analysis. Korean J Intern Med 2005;20:48-54
22. de Sonnaville JJ, Bouma M, Colly LP, et al. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40:1334-40
23. Eliasson B, Cederholm J, Nilsson P, et al. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabetic Med 2005;22:1420-6
24. Comaschi M, Coscelli C, Cucinotta D, et al. Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis 2005;15:204-11
25. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J (Clinical Research edition) 2001;322:15-8
26. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31
27. Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458-63
28. The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977-86
29. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005;353:2643-53
30. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158: 134-40
31. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124:90-6
32. Klein R, Klein BE, Moss SE, et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169-78
33. Klein R, Klein BE, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J Am Med Assoc 1988;260:2864-71
34. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003;348:383-93
35. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Supppl 2):B21-B29
36. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
37. TBC. Long-Term Veterans Affairs Diabetes Trial 2008
38. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008;358: 2545-59
39. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
40. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
41. Selam JL, Koenen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11-20
42. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin Alc in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-74
43. 1c determination. Diabetologia 2004;47:1143-8
44. The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA(1c) measurement. Diabetologia 2007;50:2042-3
45. Monnier L, Grimaldi A, Charbonnel B, et al. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab 2004;30:35-42
46. Prevost G, Phan TM, Mounier-Vehier C, et al. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 2005;31:479-85
47. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335-42
48. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080-6
49. Sawin CT, Walder DJ, Bross DS, et al. Diabetes process and outcome measures in the Department of Veterans Affairs. Diabetes Care 2004;27:90-94
50. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83
51. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab 2003;29:6S9-18
52. Anon. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
53. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) [United Kingdom Prospective Diabetes Study Group]. Br Med J (Clinical Research edition) 2000; 320:1373-8
54. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21(Suppl 3):C19-C24
55. 1c: the gap between guidelines and clinical reality across eight countries. Amsterdam, The Netherlands: EASD; 2007
56. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999;282:1458-65
57. Hofer TP, Zemencuk JK, Hayward RA. When there is too much to do: how practicing physicians prioritize among recommended interventions. J Gen Intern Med 2004;19:646-53
58. Dixon AN, Raymond NT, Mughal S, et al. Prevalence of micro-albuminuria and hypertension in South Asians and white Europeans with type 2 diabetes: a report from the United Kingdom Asian Diabetes Study (UKADS). Diab Vase Dis Res 2006;3:22-5
59. Calvert MJ, McManus RJ, Freemantle N. The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. Fam Pract 2007;24:224-9
60. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
61. Singh R, Press M. Can we predict future improvement in glycaemic control? Diabetic Med 2008;25:170-3
62. Snoek FJ. Barriers to good glycaemic control: the patient's perspective. Int J Obes Relat Metab Disord 2000;24(Suppl 3): S12-S20
63. Ciechanowski PS, Katon WJ, Russo JE, et al. The patient-provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry 2001;158:29-35
64. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999;281:2005-12
65. Wroe J. The 3rd International DAWN summit: from research and practice to large-scale implementation. Pract Diabetes Int 2006;23:313-6
66. Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care 2008;31:1046-50
67. Larranaga I, Arteagoitia JM, Rodriguez JL, et al. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Diabetic Med 2005;22:1047-53
68. Perria C. Strategies for the introduction and implementation of a guideline for the treatment of type 2 diabetics by general practitioners (GPs) of the Lazio region of Italy (IMPLEMEG study): protocol for a cluster randomised controlled trial [ISRCTN80116232]. BMC Health Serv Res 2004;4:13
69. Schiel R, Franke S, Appel T, et al. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Ent J Med Res 2004;9:391-9
70. Valroud-Vial M, Simon D, Attali J, et al. Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme. Diabetic Med 2004;21:592-8
71. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005;118:276-84
72. Krakow D, Feulner-Krakow G. LINDA: the diabetes self-management training programme for people with type 1 or type 2 diabetes. Eur Diabetes Nursing 2007;4:106-12
73. Deakin TA, Cade JE, Williams R, et al. Structured patient education: the diabetes X-PERT programme makes a difference. Diabetic Med 2006;23:944-54
74. Qaseem A, Vijan S, Snow V, et al. Glycemic control and type 2 diabetes meltitus: the optimal hemoglobin Alc targets. A guidance statement from the American College of Physicians. Ann Int Med 2007;147:417-22
75. CDA. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003, clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003. p. 27